PAFAH2 and Sepsis: The studies so far have established that OxPAPC itself or signaling intermediates that mediate its functions on endothelium, barrier-disruptive OxPLs targeting enzymes such as PAFAH2, and structure-based synthetic analogues of barrier-protective OxPLs could be developed into therapeutics against acute endothelial dysfunction associated with injury, infection, or sepsis.